在晚期乳腺癌中使用Palbociclib Plus Letrozole的整体生存率
Dennis J Slamon1, Véronique Diéras2, Hope S Rugo3
1David Geffen School of Medicine at University of California Los Angeles, Santa Monica, CA.
概括
PALOMA-2试验发现,与安慰剂加乐相比,palbociclib加乐在晚期雌激素受体阳性/人体表皮生长因子受体2-阴性乳腺癌中没有显著改善整体存活率.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕洛马-2最初显示,在晚期乳腺癌中,对palbociclib和letrozole的无进展生存率有所改善.
- 在初级终点分析时,没有总生存 (OS) 数据可用.
- 本研究报告了来自PALOMA-2试验的二次终点OS.
研究的目的:
- 报告PALOMA-2试验的整体生存 (OS) 结果.
- 为了评估palbociclib加Letrozole与安慰剂加Letrozole在晚期ER+/HER2-乳腺癌中关于OS的疗效.
主要方法:
- 一个随机的,安慰剂对照试验,涉及666名经更年期后妇女,患有ER+/HER2-晚期乳腺癌.
- 患者接受了palbociclib加Letrozole或安慰剂加Letrozole.
- 随访时间中位数为90.1个月,观察到405例死亡.
主要成果:
- 帕尔博西克利布加莱特的中位数是53.9个月,与安慰剂相比为51.2个月 (HR,0.96;P=.34).
- 武器之间未知生存结果的不平衡使最初的解释复杂化.
- 数据恢复后,中位数的生存期为53.8个月,而49.8个月 (HR,0.92;P=.21),没有显著改善.
结论:
- 在这个患者群体中,与安慰剂加乐相比,Palbociclib加乐没有显著改善整体存活率.
- 该研究强调了完整的生存数据对于准确解释临床试验结果的重要性.
- 进一步分析完整的生存数据证实没有显著的OS益处.
更多相关视频
04:57Establishing a Competing Risk Regression Nomogram Model for Survival Data
Published on: October 23, 2020
10.2K
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.2K
相关概念视频
Cancer Survival Analysis
353
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
353
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Kaplan-Meier Approach
146
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
146
Comparing the Survival Analysis of Two or More Groups
195
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
195
